Pharmacy Daily | TGA backs rotavirus vaccines

THE Therapeutic Goods Administration has issued a statement reaffirming that Rotarix and RotaTeq are both suitable for use for the prevention of infection with rotavirus, including in babies aged 2-6 months. The move follows a similar statement by the US Food and Drug Administration (PD yesterday), with authorities looking into the vaccines after manufacturers confirmed the presence of DNA fragments from porcine circovirus type 1 (PCV1) in some batches. The TGA said it had convened an expert panel of paediatricians, immunologists and vaccine specialist which had agreed that the evidence supports the ongoing use of the vaccines as “strongly in the public interest. “Having considered all the relevant scientific information the TGA has concluded that the continued use of both vaccines is strongly supported by the weight of current evidence and the long history of safe use of the products,” the TGA said.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 10
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 10